<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845503</url>
  </required_header>
  <id_info>
    <org_study_id>SMILE</org_study_id>
    <nct_id>NCT04845503</nct_id>
  </id_info>
  <brief_title>Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer</brief_title>
  <acronym>SMILE</acronym>
  <official_title>Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the most common carcinoma in men, prostate cancer is a significant tumor entity in&#xD;
      oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent&#xD;
      therapy alternative in the non-metastatic primary situation. However, radiotherapy usually&#xD;
      stretches over a period of several weeks (7 to 8 weeks) during which the patient receives&#xD;
      irradiation on a daily basis. For this reason and for radiobiological considerations the&#xD;
      total treatment time is increasingly shortened. It has been shown in several randomized phase&#xD;
      III studies that shorting radiotherapy to about 4 weeks by increasing the single dose&#xD;
      (so-called hypofractionation) is possible. Meanwhile there is also more data on extreme&#xD;
      hypofractionation (max. 10 radiation sessions) available, however often times, extensive&#xD;
      preparations are necessary (such as the invasive introduction of markers into the prostate).&#xD;
      The current, prospective, non-randomized, multicentric, Phase II SMILE study is now testing&#xD;
      whether the MRI-guided radiotherapy with a greatly shortened radiotherapy of the prostate&#xD;
      over 5 radiation sessions is possible and safe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2028</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity or Discontinuation of Therapy</measure>
    <time_frame>Within 1 Year</time_frame>
    <description>One of the the following events are counted as an Event (Number of Participants affected):&#xD;
any urogenital or gastrointestinal grade ≥ 2 toxicity within one year after the start of RT (according to NCI CTCAE Version 5.0)&#xD;
Discontinuation of therapy, with a connection to the study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 1 year and within 5 years</time_frame>
    <description>Mortality due to study treatment or due to prostate Cancer (Number of Participants deceased)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Toxicities</measure>
    <time_frame>Within 1 year and within 5 years after start of radiotherapy</time_frame>
    <description>Number and severity of urogenital or gastrointestinal toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bPFS</measure>
    <time_frame>from start of radiotherapy (day 1) until PSA-relapse according to Phoenix-Criteria (Prostate-specific antigen (PSA) nadir + 2 ng/mL after radiotherapy), assessed up to 5 years</time_frame>
    <description>biochemical progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone therapy-free Survival</measure>
    <time_frame>from start of radiotherapy until start of hormon treatment; maximum 3 months neoadjuvant</time_frame>
    <description>Hormone therapy-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from start of radiotherapy (day 1) until death or censoring assessed up to 5 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to EORTC QLQ-C30</measure>
    <time_frame>from start of radiotherapy (day 1) until end of follow-up (up to 5 years)</time_frame>
    <description>Quality of life according to EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to EORTC QLQ-PR25</measure>
    <time_frame>from start of radiotherapy (day 1) until end of follow-up (up to 5 years)</time_frame>
    <description>Quality of life according to EORTC QLQ-PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms and Toxicity</measure>
    <time_frame>from start of radiotherapy (day 1) until end of follow-up (up to 5 years)</time_frame>
    <description>Symptoms and Toxicity according to NCI CTCAE (Rate)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MR-guided Radiotherapy (5 x 7,5 Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 x 7,5 Gy prescribed on the PTV</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MR-guided Radiotherapy</intervention_name>
    <description>Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks</description>
    <arm_group_label>MR-guided Radiotherapy (5 x 7,5 Gy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed prostate carcinoma with tissue classification according to&#xD;
             Gleason score and PSA&#xD;
&#xD;
          -  low- or intermediate-risk carcinoma according to d'Amico criteria or early high-risk&#xD;
             Carcinoma (cT3a and / or GS ≤ 8 and / or PSA ≤ 20ng / ml)&#xD;
&#xD;
          -  IPSS (International Prostate Symptom Score) max. 12&#xD;
&#xD;
          -  Prostate volume &lt;80cm³&#xD;
&#xD;
          -  Karnofsky index ≥ 70%&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient information provided and written consent&#xD;
&#xD;
          -  Ability of the patient to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy in the pelvis&#xD;
&#xD;
          -  Previous local therapy of the prostate&#xD;
&#xD;
          -  lymphogenic metastasis&#xD;
&#xD;
          -  Stage IV (distant metastases)&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Simultaneous participation in another clinical study which could influence results of&#xD;
             either of the respective study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Körber, PD Dr.</last_name>
      <phone>+496221568202</phone>
      <email>Studien.Radonk@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Körber, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Medical Director RadioOncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

